Exploring how diet and gut bacteria affect chemotherapy response in pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between dietary patterns and the gut microbiome in patients with pancreatic ductal adenocarcinoma undergoing neoadjuvant chemotherapy. It aims to evaluate how the diversity of the fecal microbiome and the Healthy Eating Index (HEI-2015) dietary score correlate with the patients' response to treatment. Participants will complete a dietary survey and provide fecal samples for analysis. The findings could help tailor dietary recommendations to improve treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \* Age ≥ 18 years with signed informed consent form

  * Patients must have a histological diagnosis of PDAC
  * Resectable or borderline resectable PDAC on imaging

Exclusion Criteria:

* \* Patients with locally advanced and metastatic stage IV PDAC

  * Patients who have already received or completed neoadjuvant chemotherapy for PDAC
  * Patients with active malignancy receiving systemic therapy

Where it's running

• Emory University Hospital/Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Mihir M Shah — Emory University Hospital/Winship Cancer Institute
• Study coordinator: Mihir M. Shah, MD, FACS, FSSO
• Email: mihir.m.shah@emory.edu
• Phone: 404-778-3307

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SMAD4-tailored neoadjuvant therapy for pancreatic cancer that can be surgically removed

  This trial tests whether using SMAD4 mutation status can guide pre-surgery chemotherapy for patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT07748611

• Samuraciclib given before surgery or chemotherapy for certain pancreatic cancers

  This study tests whether taking samuraciclib before standard treatment is safe and helps patients with localized pancreatic cancer.

  Recruiting Phase 1 University of Washington · Seattle, Washington · NCT07645651

• Tumor DNA and protein testing to understand pancreatic cancer treatment response

  This trial will test whether measuring tumor DNA and proteins from people with resectable or locally advanced pancreatic ductal adenocarcinoma can be done quickly enough and provide information about how their cancer responds to standard chemotherapy.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06574620

• Neoadjuvant chemotherapy for resectable pancreatic cancer

  This study is testing a combination of three chemotherapy drugs to see if it helps people with resectable pancreatic cancer get better before surgery.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia and 1 other locations · NCT06423326

• Imaging cancer-associated fibroblasts in localized pancreatic cancer

  This study is testing a special type of scan to see if it can help find certain cells in patients with localized pancreatic cancer and predict how well they will do after surgery.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT05518903

• Targeted therapy for pancreatic cancer using new drugs

  This study is testing new targeted therapies for pancreatic cancer to see how well they work and if they are safe for patients at different stages of the disease.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT04005690

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.